Colistin A and colistin B among inhibitory substances of Paenibacillus polymyxa JB05-01-1
- PDF / 472,410 Bytes
- 8 Pages / 595 x 791 pts Page_size
- 56 Downloads / 186 Views
ORIGINAL PAPER
Colistin A and colistin B among inhibitory substances of Paenibacillus polymyxa JB05-01-1 Karim Naghmouchi · Riadh Hammami · Ismail Fliss · Ron Teather · John Baah · Djamel Drider
Received: 9 July 2011 / Revised: 25 September 2011 / Accepted: 3 October 2011 / Published online: 30 October 2011 © Springer-Verlag 2011
Abstract Recently, we isolated and reported the antagonism of Paenibacillus polymyxa JB05-01-1 (P. polymyxa JB05-01-1) against Gram-negative bacteria. Here, we provide more insights and attribute the abovementioned antagonism to the production of colistins A and B, which were puriWed by Amberlite column exchange, C18 column hydrophobicity, superdex 75 16/60 gel Wltration chromatography connected to fast protein liquid chromatography and identiWed by MALDI TOF/TOF, and manual nanospray analysis. The amount of colistin A and colistin B recovered from 500 ml of culture supernatant was about 0.05 mg. The speciWc activity and the average recovery of the eluted substances were 5,120 AU/mg and 1.1%, respectively. The minimal inhibitory concentrations of the puriWed colistins against Escherichia coli O157:H7 and Pseudomonas Xuorescens LRC R73 were 0.13 and 0.62 g/ ml, respectively. Keywords Colistin · Paenibacillus polymyxa JB05-01-1 · Antagonism · Escherichia coli
Communicated by Erko Stackebrandt. K. Naghmouchi · R. Teather · J. Baah Lethbridge Research Center, Agriculture and Agri-Food Canada, Lethbridge, AB, Canada R. Hammami · I. Fliss STELA Dairy Research Center, Nutraceuticals and Functional Foods Institute, Université Laval, Quebec, QC G1K 7P4, Canada D. Drider (&) Laboratoire des Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGEM), UPRES-EA 1026, Polytech’Lille/IUTA, Université Lille Nord de France, Avenue Paul Langevin, 59655 Villeneuve d’Ascq Cedex, France e-mail: [email protected]
Introduction Among antimicrobial substances produced by Bacillus polymyxa are polymyxins, which are cyclic peptides with a long hydrophobic tail. Colistin is a polymyxin antibiotic discovered in the late 1940s for the treatment of Gram-negative infections. After several years of clinical use, colistin was associated with signiWcant nephrotoxicity and neurotoxicty (Lim et al. 2010), rendering its use questionable. Colistin has a bactericidal eVect against Gram-negative bacteria and acts as a detergent-like molecule (Landman et al. 2008). Recently, its application has returned as the last resort against multidrug-resistant organisms including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae (Falagas and Kasiakou 2005). The need for antibiotics with activity against these multidrug-resistant Gram-negative pathogens is urgent, and in the absence of viable alternatives, clinicians now recommend colistin treatment when confronted with some multidrug-resistant bacterial infections (Lim et al. 2010). This has led to the development of less toxic colistin molecules (Li et al. 2004; Falagas and Kasiakou 2006). Colistin formulations available for clinical uses are co
Data Loading...
